Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Aluminum salts in vaccines--US perspective.

Baylor NW, Egan W, Richman P.

Vaccine. 2002 May 31;20 Suppl 3:S18-23. Review. Erratum in: Vaccine. 2002 Sep 10;20(27-28):3428.

PMID:
12184360
2.

The global impact of vaccines containing aluminium adjuvants.

Clements CJ, Griffiths E.

Vaccine. 2002 May 31;20 Suppl 3:S24-33. Review.

PMID:
12184361
3.

[Aluminum as an adjuvant in vaccines and post-vaccine reactions].

Fiejka M, Aleksandrowicz J.

Rocz Panstw Zakl Hig. 1993;44(1):73-80. Review. Polish.

PMID:
8235346
4.

Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence.

Jefferson T, Rudin M, Di Pietrantonj C.

Lancet Infect Dis. 2004 Feb;4(2):84-90. Review.

PMID:
14871632
5.

Adjuvants for vaccines to drugs of abuse and addiction.

Alving CR, Matyas GR, Torres O, Jalah R, Beck Z.

Vaccine. 2014 Sep 22;32(42):5382-9. doi: 10.1016/j.vaccine.2014.07.085. Epub 2014 Aug 8. Review.

6.

Structure and properties of aluminum-containing adjuvants.

Hem SL, White JL.

Pharm Biotechnol. 1995;6:249-76. Review.

PMID:
7551220
7.

Current adjuvants and new perspectives in vaccine formulation.

Montomoli E, Piccirella S, Khadang B, Mennitto E, Camerini R, De Rosa A.

Expert Rev Vaccines. 2011 Jul;10(7):1053-61. doi: 10.1586/erv.11.48. Review.

PMID:
21806399
8.

Overview of vaccine adjuvants: present and future.

Hunter RL.

Vaccine. 2002 May 31;20 Suppl 3:S7-12. Review.

PMID:
12184369
9.

Mechanisms of stimulation of the immune response by aluminum adjuvants.

HogenEsch H.

Vaccine. 2002 May 31;20 Suppl 3:S34-9. Review.

PMID:
12184362
10.

Advances in aluminum hydroxide-based adjuvant research and its mechanism.

He P, Zou Y, Hu Z.

Hum Vaccin Immunother. 2015;11(2):477-88. doi: 10.1080/21645515.2014.1004026. Review.

11.

Vaccine adjuvants.

Edelman R.

Rev Infect Dis. 1980 May-Jun;2(3):370-83. Review.

PMID:
6997966
12.

Adjuvants in veterinary vaccines: modes of action and adverse effects.

Spickler AR, Roth JA.

J Vet Intern Med. 2003 May-Jun;17(3):273-81. Review.

13.

Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation.

Hem SL, Hogenesch H.

Expert Rev Vaccines. 2007 Oct;6(5):685-98. Review.

PMID:
17931150
15.

[Adverse reactions to vaccines].

Eseverri JL, Ranea S, Marin A.

Allergol Immunopathol (Madr). 2003 May-Jun;31(3):125-38. Review. Spanish.

PMID:
12783762
17.

Improving vaccine delivery using novel adjuvant systems.

Pichichero ME.

Hum Vaccin. 2008 Jul-Aug;4(4):262-70. Epub 2008 Feb 15. Review.

PMID:
18398303
18.

Design and selection of vaccine adjuvants: animal models and human trials.

Alving CR.

Vaccine. 2002 May 31;20 Suppl 3:S56-64. Review.

PMID:
12184368
19.

Adjuvants: present regulatory challenges.

Pascual DM, Morales RD, Gil ED, Muñoz LM, López JE, Casanueva OL.

Vaccine. 2006 Apr 12;24 Suppl 2:S2-88-9. Review.

PMID:
16823941
20.

Regulatory considerations on new adjuvants and delivery systems.

Sesardic D.

Vaccine. 2006 Apr 12;24 Suppl 2:S2-86-7. Review.

PMID:
16823940
Items per page

Supplemental Content

Write to the Help Desk